Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus BETAMETHASONE DIPROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus BETAMETHASONE DIPROPIONATE.
A-HYDROCORT vs BETAMETHASONE DIPROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Category C
Category D/X
Corticosteroid
Corticosteroid